Nasopharyngeal News and Research

RSS

Urinary pneumococcal antigen testing ‘useful in children’

Urinary antigen testing is effective in detecting invasive pneumococcal pneumonia in children, say the authors of a UK-based case–control study.

23 Sep 2013

Coronavirus incubation period may be longer than previously thought

A detailed clinical description of two cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in France, published online in The Lancet today, suggests that the incubation period for the virus may be longer than previously thought, and longer quarantine periods may be required to rule out infection among patient contacts.

29 May 2013

Newly characterized adenoviruses can cause severe human infections

The ongoing dance between a virus and its host distinctly shapes how the virus evolves. While human adenoviruses typically cause mild infections, recent reports have described newly characterized adenoviruses that can cause severe, sometime fatal, human infections.

12 Apr 2013

Experts provide guidebook for surgeons dealing with head and neck neoplasms

In this unique volume, leading international experts share their experiences in the management of head and neck tumors, providing a guidebook for all surgeons dealing with head and neck neoplasms.

21 Mar 2013

Nursing home patients with pneumonia may need viral screening

Viral testing should be carried out among all older individuals who have been admitted to hospital for nursing home-acquired pneumonia, recommend researchers.

5 Mar 2013

Researchers identify second B-cell attachment receptor for Epstein-Barr virus

Epstein-Barr virus (EBV) affects more than 90 percent of the population worldwide and was the first human virus found to be associated with cancer. Now, researchers from Beth Israel Deaconess Medical Center (BIDMC) have broadened the understanding of this widespread infection with their discovery of a second B-cell attachment receptor for EBV.

21 Feb 2013

Study offers new evidence of natural emission of influenza

A new study suggests that patients with influenza can emit small virus-containing particles into the surrounding air during routine patient care, potentially exposing health care providers to influenza. Published in The Journal of Infectious Diseases, the findings raise the possibility that current influenza infection control recommendations may not always be adequate to protect providers from influenza during routine patient care in hospitals.

2 Feb 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Nasopharyngeal cancer patients at risk for stroke

Patients with nasopharyngeal cancer are at an increased risk for ischemic stroke, particularly if comorbidities are present, report researchers.

18 Dec 2012

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Alverix, Inc., a world leader in the design and manufacture of next-generation platforms for diagnostic Point-of-Care (POC) testing, today announced that BD Diagnostics, a segment of Becton Dickinson and Company, a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD VeritorTM System for Rapid Detection of respiratory syncytial virus (RSV).

12 Oct 2012

Bacterial pathogen ‘acutely’ involved in otitis media

Alloiococcus otitidis can be a dominant bacterial pathogen among indigenous Australian children with acute otitis media with perforation, although its main role appears to be that of a secondary pathogen, preliminary study findings suggest.

10 Oct 2012

Genocea raises $30M in Series C financing round

Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round.

10 Oct 2012

Montelukast possible surgery alternative for obstructive sleep apnea

Leukotriene modifiers may provide a noninvasive treatment option for children with nonsevere obstructive sleep apnea, say researchers.

13 Sep 2012

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Researchers from The Wistar Institute and Memorial Sloan-Kettering Cancer Center (MSKCC) have teamed to publish the first annotated atlas of the Epstein-Barr virus genome, creating the most comprehensive study of how the viral genome interacts with its human host during a latent infection. Epstein-Barr virus (EBV), which is thought to be responsible for one percent of all human cancers, establishes a latent infection in nearly 100 percent of infected adult humans.

24 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Guidebook for surgeons dealing with head and neck neoplasms

In this unique volume, leading international experts share their experiences in the management of head and neck tumors, providing a guidebook for all surgeons dealing with head and neck neoplasms.

12 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.

8 Feb 2012